Clinical study to assess an Ayurvedic combination as a tablet orally and as an ointment for external application in patients affected with Psoriasis

Single centre open label pilot clinical trial to assess the efficacy of a combination of 1g Psorakot oral tablets (two tablets thrice daily) and Psorakot gel external application (twice daily) in subjects with moderate to severe psoriasis over a period of 6 weeks

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/02/007812

Enrollment

Registered

2017-02-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Moderate to Severe Psoriasis Health Condition 2: L409- Psoriasis, unspecified

Interventions

Intervention1: Psorakot tablet 1g 2 tablets thrice daily after food orally for 45 days: Prepared in Vaidyaratnam PS Varriers Aryavaidya sala, Kottakkal Intervention2: Psorakot gel external application

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with active, stable psoriasis defined by the following criteria: a.DLQI > 10 at baseline 2.Patients who are willing to sign the informed consent form and agree to return to follow-up visits.

Exclusion criteria

Exclusion criteria: 1.Patients who were making use of biologics, corticosteroids or nonsteroidal anti-inflammatory and non-steroid, or who made use of these topical medications until 15 days before inclusion or 30 days before inclusion when the administration was orally. 2.Patients with evidence of Skin conditions other than psoriasis. 3.Patients who also had psoriatic plaques of skin disorders caused by fungi or bacteria and they were making use of antibiotic or antifungal. 4.Patients using Psoralen plus ultraviolet radiation (PUVA), cyclosporine, alefacept, methotrexate, acitretin, or any other systemic anti-psoriasis therapy within 28 days of study drug initiation 5.Pregnant and/or nursing women 6.Patients using oral anticoagulants

Design outcomes

Primary

Measure	Time frame
Simplified Psoriasis Index â?¢Self assessment â?¢Professional assessment Timepoint: Day1,Day15,Day30,Day45	—

Secondary

Measure	Time frame
Ayurvedic QuestionnaireTimepoint: Day1,Day15,Day30,Day45;Dermatology Life Quality IndexTimepoint: Day1,Day15,Day30,Day45 ;Photographs of target areaTimepoint: Day1,Day15,Day30,Day45 ;Psoriasis Disability IndexTimepoint: Day1,Day15,Day30,Day45;Psoriasis Life Stress InventoryTimepoint: Day1,Day15,Day30,Day45	—

Countries

India

Contacts

Public ContactSreejith Sreekumar

Vaidyaratnam P. S. Variers Arya Vaidya Sala, Kottakkal

varier.praveen@gmail.com0483-2742212

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026